CD4 and type 1 diabetes mellitus: Here, we investigate autoreactive CD4+ T cells specific for epitopes in islet proteins as potential biomarkers that at baseline predict response to alefacept in new-onset T1D patients enrolled in the T1DAL clinical trial.